Cosentyx May Increase Risk for Inflammatory Bowel Disease, Italian Researchers Say

Cosentyx May Increase Risk for Inflammatory Bowel Disease, Italian Researchers Say
Italian researchers are calling attention to what they say is an alarming number of newly diagnosed cases of inflammatory bowel disease (IBD) in people treated with the human monoclonal antibody Cosentyx (secukinumab). Their report was published in an open letter to the editor in the The American Journal of Gastroenterologytitled "New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series.” Cosentyx, developed by
Subscribe or to access all post and page content.